<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100731">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01788059</url>
  </required_header>
  <id_info>
    <org_study_id>900939</org_study_id>
    <nct_id>NCT01788059</nct_id>
  </id_info>
  <brief_title>The Efficacy of Mesenchymal Stem Cells for Stimulate the Union in Treatment of Non-united Tibial and Femoral Fractures in Shahid Kamyab Hospital</brief_title>
  <official_title>The Efficacy of Mesenchymal Stem Cells for Stimulate the Union in Treatment of Non-united Tibial and Femoral Fractures in Shahid Kamyab Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emdadi Kamyab Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emdadi Kamyab Hospital</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because the rate of non union of long bone in lower extremities specially in tibia in this
      two last decade due to malnutrition and smoking and other risk factors was increased, so
      many patient in our country suffer from non union on the other hand it seems that the use of
      the mesenchymal  stem cells can irritate the union rate. Therefore the investigators decide
      to inject the mesenchymal stem cell derived from iliac bone marrow after centrifuge with
      ficoll procedure to non union site in patient that are resistant to other treatment. Then
      the investigators will follow the patient with monthly radiography and evaluate the callus
      volume and clinical union and any side effect of this treatment.clinical union consider to
      relief pain in non union site and be stable in examination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>clinical and radiological union at 1 month to 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>patients receiving Mesenchymal Stem Cells that develop a partial or complete callus at 1, 2, 3, 4 ,5 and 6 months evaluate with  standard X-rays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>â€¢Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events in patients (e.g infection , malignancy , ...)  Adverse events  will be continuously monitored</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Nonunion Fracture</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with  approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>injection the mesenchymal stem cell in non union site</intervention_name>
    <arm_group_label>mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Every patient with non union in the site of long bone fracture

          -  Age more than 18 and under 60 years old

          -  Fracture having no radiological callus after 6 months and absence of any hypertrophic
             bone reaction.

          -  No infection in site of surgery

          -  Be able and willing to participate in the study

          -  Written informed consent

        Exclusion Criteria:

          -  Evidence of malignancy

          -  Pregnancy or breastfeeding

          -  Patient positive by serology or PCR for HIV, hepatitis B or C infection the patient
             with Accompanied fracture such as hip fracture that could not weight bearing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohammad taghi peivandi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emdadi Kamyab Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emdai Kamyab Hospital</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 26, 2013</lastchanged_date>
  <firstreceived_date>January 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emdadi Kamyab Hospital</investigator_affiliation>
    <investigator_full_name>mohammad taghi peivandi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>nonunion</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>long bone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Femoral Fractures</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Ununited</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
